This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor.—Dr Catalona and colleagues¹ have demonstrated that 20% of biopsies can be eliminated in men whose total prostate-specific antigen (PSA) levels fall in the borderline range (4.0-10.0 ng/mL) and who have a normal digital rectal examination (DRE) by using free PSA monoclonal antibody assays. They reported that of all the patients with total PSA results within this range, only 5% of those with cancers would be missed. Because the likelihood of a positive biopsy finding would increase as the PSA increased within the given range, the authors should analyze their data by looking at only performing biopsies on men with PSA levels between 5.0 and 10.0 ng/mL or between 6.0 and 10.0 ng/mL. It would seem reasonable to assume that a higher proportion of positive biopsies would be found within the group of men still undergoing biopsies, so a smaller number of biopsies would be performed. The . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial
William J. Catalona, Alan W. Partin, Kevin M. Slawin, Michael K. Brawer, Robert C. Flanigan, Anup Patel, Jerome P. Richie, Jean B. deKernion, Patrick C. Walsh, Peter T. Scardino, Paul H. Lange, Eric N. P. Subong, Robert E. Parson, Gail H. Gasior, Kathleen G. Loveland, and Paula C. Southwick
JAMA. 1998;279(19):1542-1547.
ABSTRACT | FULL TEXT